Kenvue Inc.

Kenvue sells daily-use consumer health products with strong repeat-purchase dynamics across pharmacy, retail, and grocery channels, providing moderate baseline stability. Revenue ranged from $14.3B to $15.5B over FY2019-FY2025, but the business is not contractual or subscription-based, and FY2025 organic sales declined 2.2%, illustrating vulnerability to promotion dynamics and consumer trade-down.

Kenvue operates three distinct segments: Self Care (42% of FY2025 net sales), Essential Health (30%), and Skin Health and Beauty (27%), spanning OTC drugs, oral care, wound care, and personal care categories. The segments serve different consumer needs and competitive dynamics, though all operate within the consumer health space.

No single country contributes more than approximately 30% of net sales (the United States at ~30% in FY2025), with EMEA at ~16%, Asia Pacific at ~13%, and Latin America at ~6% contributing meaningfully alongside North America at ~34% overall. The multi-regional footprint across four distinct revenue-generating regions reduces single-country regulatory, economic, and currency risk.

Consumer health manufacturing is capital- and labor-intensive, limiting inherent operating leverage compared to software or asset-light businesses. The 'Our Vue Forward' multi-year restructuring program has supported gross margin, but revenue has been flat over FY2019-FY2025, constraining the demonstration of durable scale economics.

Kenvue's categories including OTC pain, oral care, wound care, and skin care are predominantly non-discretionary daily-use products with strong pharmacist and physician recommendation channels. Repeat-purchase loyalty supports quality without true lock-in; products are easily substituted by generics or store brands when price gaps widen, limiting the depth of customer commitment.